Preliminary confirmation of safety read-out from the fimaChem Phase I extension study in bile duct cancer

Posted on Dec 20, 2018

Oslo (Norway), 20 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced preliminary confirmation that the safety endpoint has been reached in the Phase I extension study without the report of any adverse reactions which would limit the proposed plan of including up to two fimaCHEM treatments in the pivotal […]

Extension of preclinical research collaboration agreement with a top-10 large pharma company

Posted on Dec 18, 2018

Oslo (Norway), 18 December 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company, initiated in September 2015. The extended evaluation period spans over 6 months, until the end of June 2019, and may be further extended. The […]

Third quarter 2018 results

Posted on Nov 13, 2018

Oslo (Norway), 13 November 2018 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announces its interim third quarter 2018 result. Please find enclosed the report and presentation. The fully underwritten rights issue of NOK 360 million completed in October 2018 provides PCI Biotech with the funds needed for the pivotal fimaCHEM study, […]